Riskpilot← Back to searchSign inGet full accessEvitraproteoma AB
ABActiveOrg 5566572318Grusåsgränd 138Research and experimental development on natural sciences and engineering · NACE 7210Est. 20040 employees
Revenue 2024
SEK 0
EBITDA margin
—
+18% vs 2023
Equity ratio
98.2%
Financial strength
Net profit 2024
SEK 384K
+15% vs 2023
| Revenue | SEK 0 | — |
| EBITDA | SEK 265K | +18% |
| Net profit | SEK 384K | +15% |
| Total assets | SEK 1,2M | +48% |
| Equity | SEK 1,2M | +49% |
| Employees | 0 | — |
Legal name
Evitraproteoma AB
Org number
5566572318
Legal form
Aktiebolag
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
8 mars 2004
Share capital
SEK 100 000
Employees
0
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas var för sig av ledamöterna
Company purpose
Bolaget skall bedriva verksamhet inom området bioteknologi med proteinproduktion som huvudsyssla samt idka därmed förenlig verksamhet. Föremål för bolagets verksamhet är produktion av proteiner och att sälja uppdragsforskning och licensiera ut en metod för proteinproduktion baserad på bolagets patent och teknologi och därmed förenlig verksamhet.
Address
Grusåsgränd 138
Email
tobias.cornvik@gmail.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 126 | 120 | 0 | 0 | 0 |
| Staff expenses | — | — | — | — | — |
| EBITDA | −6 | 22 | −151 | 226 | 265 |
| Depreciation & amort. | −0 | −0 | — | — | — |
| EBIT | −6 | 22 | −151 | 226 | 265 |
| Net financials | 53 | 205 | 75 | 109 | 162 |
| Profit before tax | 49 | 194 | −76 | 335 | 428 |
| Tax | −7 | −0 | — | — | −43 |
| Net profit | 42 | 194 | −76 | 335 | 384 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 350 | 540 | 462 | 798 | 1 183 |
| Equity | 325 | 519 | 443 | 777 | 1 162 |
| Long-term debt | 0 | 14 | 14 | 14 | 14 |
| Short-term debt | 25 | 7 | 5 | 7 | 7 |
| Total debt | 25 | 21 | 19 | 20 | 21 |
EBITDA margin
26549200.0%
This company
15.8%
Market median
+168032811% vs market
20202024
Equity ratio
98.2%
This company
38.2%
Market median
+157% vs market
20202024
Return on equity
33.1%
This company
18.4%
Market median
+80% vs market
20202024
Net profit margin
38449800.0%
This company
8.1%
Market median
+474688789% vs market
20202024
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20202024
Debt / equity
0.02×
This company
0.62×
Market median
+97% vs market
20202024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
No data on file.
| Name | Role | Member since |
|---|---|---|
| Current (3) | ||
| Chairman | 2025 | |
| Board of Directors | 2022 | |
| Deputy Board Member | 2025 | |
| Former (2) | ||
| Chairman | 2022 – 2025 | |
| Deputy Board Member | 2022 – 2025 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Evitraproteoma AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Pär Lennart Nordlund | Chairman | 0 companies |
| Tobias Carl Cornvik | Chairman | 0 companies |
| Sue-Li Katarina Sandra Dahlroth | Board of Directors | 0 companies |
| Erik Andreas Larsson | Deputy Board Member | 0 companies |
| Lena Birgitta Lindgren | Deputy Board Member | 0 companies |